These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

324 related articles for article (PubMed ID: 34376155)

  • 1. Prospective comparison of early interim
    Su TP; Huang JS; Chang PH; Lui KW; Hsieh JC; Ng SH; Chan SC
    BMC Cancer; 2021 Aug; 21(1):908. PubMed ID: 34376155
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Can 3'-deoxy-3'-(18)F-fluorothymidine or 2'-deoxy-2'-(18)F-fluoro-d-glucose PET/CT better assess response after 3-weeks treatment by epidermal growth factor receptor kinase inhibitor, in non-small lung cancer patients? Preliminary results.
    Bhoil A; Singh B; Singh N; Kashyap R; Watts A; Sarika S; Mittal BR
    Hell J Nucl Med; 2014; 17(2):90-6. PubMed ID: 24997081
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 3'-deoxy-3'-[¹⁸F]-fluorothymidine PET/CT in early determination of prognosis in patients with esophageal squamous cell cancer: comparison with [¹⁸F]-FDG PET/CT.
    Chen H; Li Y; Wu H; Sun L; Lin Q; Zhao L; An H
    Strahlenther Onkol; 2015 Feb; 191(2):141-52. PubMed ID: 25163419
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early determination of prognosis by interim 3'-deoxy-3'-18F-fluorothymidine PET in patients with non-Hodgkin lymphoma.
    Lee H; Kim SK; Kim YI; Kim TS; Kang SH; Park WS; Yun T; Eom HS
    J Nucl Med; 2014 Feb; 55(2):216-22. PubMed ID: 24365650
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 3'-Deoxy-3'-
    Kim JE; Chae SY; Kim JH; Kim HJ; Kim TW; Kim KP; Kim SY; Lee JL; Oh SJ; Kim JS; Ryu JS; Moon DH; Hong YS
    Eur J Nucl Med Mol Imaging; 2019 Jul; 46(8):1713-1722. PubMed ID: 31041456
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diffuse Large B-Cell Lymphoma: Prospective Multicenter Comparison of Early Interim FLT PET/CT versus FDG PET/CT with IHP, EORTC, Deauville, and PERCIST Criteria for Early Therapeutic Monitoring.
    Minamimoto R; Fayad L; Advani R; Vose J; Macapinlac H; Meza J; Hankins J; Mottaghy F; Juweid M; Quon A
    Radiology; 2016 Jul; 280(1):220-9. PubMed ID: 26854705
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The predictive value of
    Mattoli MV; Massaccesi M; Castelluccia A; Scolozzi V; Mantini G; Calcagni ML
    Radiat Oncol; 2017 Jan; 12(1):4. PubMed ID: 28057034
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quantitative analysis of response to treatment with erlotinib in advanced non-small cell lung cancer using 18F-FDG and 3'-deoxy-3'-18F-fluorothymidine PET.
    Kahraman D; Scheffler M; Zander T; Nogova L; Lammertsma AA; Boellaard R; Neumaier B; Ullrich RT; Holstein A; Dietlein M; Wolf J; Kobe C
    J Nucl Med; 2011 Dec; 52(12):1871-7. PubMed ID: 22065872
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of FDG-PET/CT and contrast-enhanced CT for monitoring therapy response in patients with metastatic breast cancer.
    Riedl CC; Pinker K; Ulaner GA; Ong LT; Baltzer P; Jochelson MS; McArthur HL; Gönen M; Dickler M; Weber WA
    Eur J Nucl Med Mol Imaging; 2017 Aug; 44(9):1428-1437. PubMed ID: 28462446
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predicting tumor response and outcome of second-look surgery with
    Aide N; Fauchille P; Coquan E; Ferron G; Combe P; Meunier J; Alexandre J; Berton D; Leary A; De Rauglaudre G; Bonichon N; Pujade Lauraine E; Joly F
    Eur J Nucl Med Mol Imaging; 2021 Jun; 48(6):1998-2008. PubMed ID: 33221969
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Using positron emission tomography (PET) response criteria in solid tumours (PERCIST) 1.0 for evaluation of 2'-deoxy-2'-[18F] fluoro-D-glucose-PET/CT scans to predict survival early during treatment of locally advanced non-small cell lung cancer (NSCLC).
    Fledelius J; Khalil AA; Hjorthaug K; Frøkiaer J
    J Med Imaging Radiat Oncol; 2016 Apr; 60(2):231-8. PubMed ID: 26678718
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prospective Study of Serial
    Peterson LM; O'Sullivan J; Wu QV; Novakova-Jiresova A; Jenkins I; Lee JH; Shields A; Montgomery S; Linden HM; Gralow J; Gadi VK; Muzi M; Kinahan P; Mankoff D; Specht JM
    J Nucl Med; 2018 Dec; 59(12):1823-1830. PubMed ID: 29748233
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictive value of early and late residual 18F-fluorodeoxyglucose and 18F-fluorothymidine uptake using different SUV measurements in patients with non-small-cell lung cancer treated with erlotinib.
    Kobe C; Scheffler M; Holstein A; Zander T; Nogova L; Lammertsma AA; Boellaard R; Neumaier B; Ullrich RT; Dietlein M; Wolf J; Kahraman D
    Eur J Nucl Med Mol Imaging; 2012 Jul; 39(7):1117-27. PubMed ID: 22526960
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TLG-S criteria are superior to both EORTC and PERCIST for predicting outcomes in patients with metastatic lung adenocarcinoma treated with erlotinib.
    Ho KC; Fang YD; Chung HW; Liu YC; Chang JW; Hou MM; Yang CT; Cheng NM; Su TP; Yen TC
    Eur J Nucl Med Mol Imaging; 2016 Nov; 43(12):2155-2165. PubMed ID: 27260520
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prospective Study of 3'-Deoxy-3'-18F-Fluorothymidine PET for Early Interim Response Assessment in Advanced-Stage B-Cell Lymphoma.
    Schöder H; Zelenetz AD; Hamlin P; Gavane S; Horwitz S; Matasar M; Moskowitz A; Noy A; Palomba L; Portlock C; Straus D; Grewal R; Migliacci JC; Larson SM; Moskowitz CH
    J Nucl Med; 2016 May; 57(5):728-34. PubMed ID: 26719374
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 2-[
    Vogsen M; Naghavi-Behzad M; Harbo FG; Jakobsen NM; Gerke O; Asmussen JT; Nissen HJ; Dahlsgaard-Wallenius SE; Braad PE; Jensen JD; Ewertz M; Hildebrandt MG
    Sci Rep; 2023 Apr; 13(1):5552. PubMed ID: 37019987
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor response to neoadjuvant chemotherapy in patients with esophageal cancer assessed with CT and FDG-PET/CT - RECIST 1.1 vs. PERCIST 1.0.
    Odawara S; Kitajima K; Katsuura T; Kurahashi Y; Shinohara H; Yamakado K
    Eur J Radiol; 2018 Apr; 101():65-71. PubMed ID: 29571803
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A pilot study for texture analysis of
    Nakajo M; Kajiya Y; Tani A; Jinguji M; Nakajo M; Kitazono M; Yoshiura T
    Eur J Nucl Med Mol Imaging; 2017 Dec; 44(13):2158-2168. PubMed ID: 28770274
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of
    Mori M; Fujioka T; Ichikawa R; Inomata R; Katsuta L; Yashima Y; Yamaga E; Tsuchiya J; Hayashi K; Kumaki Y; Oda G; Nakagawa T; Onishi I; Kubota K; Tateishi U
    Tomography; 2022 Oct; 8(5):2533-2546. PubMed ID: 36287810
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic value of interim fluorodeoxyglucose and fluorothymidine PET/CT in diffuse large B-cell lymphoma.
    Wang R; Xu B; Liu C; Guan Z; Zhang J; Li F; Sun L; Zhu H
    Br J Radiol; 2018 Nov; 91(1091):20180240. PubMed ID: 30004787
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.